Hospitals
There are 682 hospitals in Beijing, including many world-class hospitals and national-level medical centers, such as the Beijing Cancer Hospital, widely recognized for its research and clinical innovation.
Description
Beijing is rapidly cementing its status as a premier global life sciences hub, uniquely characterized by its high-density integration of academic research and industrial commercialization. As the centerpiece of China’s "innovation-driven" national strategy, the city is best known for its elite biotechnology clusters, such as Zhongguancun Life Science Park and the newly launched International BioPark in E-Town. These hubs serve as a magnet for multinational pharmaceutical companies like AstraZeneca and Pfizer, who are increasingly localizing innovative drug R&D and biomanufacturing operations within the capital.
The ecosystem’s competitive edge is anchored by world-class institutions like Peking University and Tsinghua University, which provide a steady pipeline of top-tier talent for translational medicine and foundational life sciences research. Beijing leads the charge in frontier fields such as cell and gene therapy (CGT), antibody-drug conjugates (ADCs) and RNAi therapeutics, fueled by a robust venture capital environment.
Furthermore, the city is at the forefront of healthcare innovation, pioneering the use of AI-driven drug discovery and smart medical devices through its "AI Plus" industrial strategy.
With streamlined NMPA regulatory pathways and a growing focus on precision medicine, Beijing offers a comprehensive environment for clinical trials and the rapid market entry of high-end medical equipment.
Beijing remains a critical gateway for global stakeholders looking to tap into the next generation of bioeconomy breakthroughs.
Featured Editorial
Universities
Home to elite universities like Tsinghua University, Peking University, Capital Medical University and institutions of the Chinese Academy of Sciences, Beijing has a total of at least 90 universities and colleges.
Government Funding
In April 2025, Beijing launched a “mega science plan” at Huairou Science City to advance life and medical sciences using AI and digital technologies. Beijing is also implementing regulatory and funding support programs (e.g. for BioPark, innovation zones) that facilitate private and public investment in life sciences. This underscores the city’s strategic prioritization of biomedicine in national innovation policy.
VC Funding
Life sciences VC investment in Beijing was around $637 million in 2024
Life Science Firms
In the Beijing Economic and Technological Development Area, there are nearly 5,000 biopharma/medical health “enterprises” located in that development zone.
Big Pharma Presence
International big pharma companies like AstraZeneca have made massive investments in Beijing, namely a $2.5 billion strategic R&D and manufacturing investment, to be phased over five years, in collaboration with Beijing Cancer Hospital and biotech companies like Harbour BioMed and BioKangtai. Other notable big pharma companies with operations in Beijing include BeiGene and Novo Nordisk.
Big Medtech Presence
Some major medtech companies in Beijing include Lepu Medical Technology and Beijing Wandong Medical, specializing in medical equipment. Other notable companies include Aohua Endoscopy Co., Ltd. and Beijing AKEC Medical Co., Ltd.
Active Clinical Studies
There are currently over 4,600 clinical studies being conducted in Beijing.
